惠泰医疗(688617)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688617 惠泰医疗

已收盘 12-20 15:00:00

{"stockData":{"symbol":"688617","market":"SH","secType":"STK","nameCN":"惠泰医疗","latestPrice":346.23,"timestamp":1734678000000,"preClose":358.3,"halted":0,"volume":823965,"delay":0,"floatShares":97393799,"shares":97393799,"eps":6.7646,"marketStatus":"已收盘","marketStatusCode":5,"change":-12.07,"latestTime":"12-20 15:00:00","open":359.87,"high":359.89,"low":346.1,"amount":289000000,"amplitude":0.0385,"askPrice":346.35,"askSize":8,"bidPrice":346.23,"bidSize":0,"shortable":0,"etf":0,"ttmEps":6.7646,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"adjPreClose":358.3,"symbolType":"stock_kcb","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":394.13,"lowLimit":322.47,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":97393764,"pbRate":14.12,"roa":"--","roe":"24.39%","epsLYR":8.04,"committee":-0.185185,"marketValue":33721000000,"floatMarketCap":33721000000,"peRate":51.182629,"changeRate":-0.0337,"turnoverRate":0.0085,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-12-23。","afterMarket":{"amount":0,"volume":0,"close":346.23,"buyVolume":0,"sellVolume":0,"time":1734680038975,"indexStatus":"已收盘 12-20 15:30:00","preClose":358.3}},"requestUrl":"/m/hq/s/688617","defaultTab":"news","newsList":[{"id":"2492492900","title":"惠泰医疗将于1月6日召开股东大会，审议2025年度日常关联交易预计等议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2492492900","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492492900?lang=zh_cn&edition=full","pubTime":"2024-12-20 17:10","pubTimestamp":1734685830,"startTime":"0","endTime":"0","summary":"金融界12月20日消息，惠泰医疗发布公告，将于2025年1月6日召开第1次临时股东大会，网络投票同日进行。股权登记日为12月30日，当日收市后持有惠泰医疗股票的投资者可以参与投票。会议地点：湖南湘乡经济开发区湘乡大道009号湖南埃普特医疗器械有限公司会议室。本次股东大会共计审计4项议案，具体如下：1、《关于部分募投项目延期及调整投资金额的议案》2、《关于2025年度日常关联交易预计的议案》3、《关于调整公司回购股份用途并注销暨减少注册资本的议案》4、《关于变更注册资本暨修订<公司章程>的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220174240a1fd5a67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220174240a1fd5a67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2492976221","title":"惠泰医疗(688617.SH)获得一次性使用磁电定位压力监测脉冲电场消融导管医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2492976221","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492976221?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:57","pubTimestamp":1734508637,"startTime":"0","endTime":"0","summary":"智通财经APP讯，惠泰医疗(688617.SH)发布公告，公司全资子公司湖南埃普特医疗器械有限公司取得一项医疗器械注册证，产品名称为一次性使用磁电定位压力监测脉冲电场消融导管。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09997","159883","BK0251","BK1583","09996","688617","BK1222","BK1574","BK1100"],"gpt_icon":0},{"id":"2492377879","title":"惠泰医疗：上述政策主要面向的领域与公司业务范围不匹配","url":"https://stock-news.laohu8.com/highlight/detail?id=2492377879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492377879?lang=zh_cn&edition=full","pubTime":"2024-12-17 19:00","pubTimestamp":1734433244,"startTime":"0","endTime":"0","summary":"证券之星消息，惠泰医疗12月17日在投资者关系平台上答复投资者关心的问题。谢谢惠泰医疗董秘：尊敬的投资者，您好！上述政策主要面向的领域与公司业务范围不匹配。公司在上海建设区域中心总部大楼对公司的净资产收益率影响有限。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121700032568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688617","BK0251"],"gpt_icon":0},{"id":"2492413964","title":"研报掘金丨国盛证券：惠泰医疗PFA产品具备良好的安全性与有效性，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2492413964","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492413964?lang=zh_cn&edition=full","pubTime":"2024-12-17 15:01","pubTimestamp":1734418917,"startTime":"0","endTime":"0","summary":"国盛证券研报指出，惠泰医疗(688617.SH)PFA产品集三大特色功能于一体，具备良好的安全性与有效性。公司PFA创新产品是全球首款融合“压力感知/贴靠指示”+““ 磁电定定位三维标测”+“脉冲消融”三大特色功能于一体的消融系统，具有独特技术优势。公司PFA产品获批丰富了电生理领域产品布局，看好迈瑞入驻对公司研发和海内外销售的持续赋能。中国房颤脉冲电场消融器械占心脏电生理器械的比重也将不断提升，预计将由2025年的8.18%提升至2032年的38.87%。此外，公司在研项目加速获批，平台化公司雏形渐成。维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217150200a1f5142f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217150200a1f5142f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["161027","688617"],"gpt_icon":0},{"id":"2492266673","title":"惠泰医疗（688617）12月16日主力资金净卖出914.63万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492266673","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492266673?lang=zh_cn&edition=full","pubTime":"2024-12-17 08:23","pubTimestamp":1734395018,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月16日收盘，惠泰医疗报收于351.0元，下跌3.83%，换手率1.49%，成交量1.45万手，成交额5.09亿元。近5日资金流向一览见下表：惠泰医疗融资融券信息显示，融资方面，当日融资买入3889.26万元，融资偿还3813.87万元，融资净买入75.39万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121700007959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2492964422","title":"惠泰医疗：PFA取得NMPA认证 产品矩阵日趋丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2492964422","media":"国盛证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492964422?lang=zh_cn&edition=full","pubTime":"2024-12-17 00:00","pubTimestamp":1734364800,"startTime":"0","endTime":"0","summary":"事件：2024 年12 月16 日，惠泰医疗发布公告，公司一次性使用心脏脉冲电场消融导管、上海宏桐心脏脉冲电场消融仪获得III 类NMPA 注册证，用于治疗药物难治性、复发性、症状性、阵发性房颤，其中一次性使用心脏脉冲电场消融导管用于肺静脉口和前庭消融。公司PFA 产品集三大特色功能于一体，具备良好的安全性与有效性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217124229ab7e24d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217124229ab7e24d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2491668114","title":"惠泰医疗(688617.SH)取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2491668114","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491668114?lang=zh_cn&edition=full","pubTime":"2024-12-16 18:04","pubTimestamp":1734343456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，惠泰医疗(688617.SH)发布公告，近日，公司取得一项医疗器械注册证，产品名称：一次性使用心脏脉冲电场消融导管。全资子公司上海宏桐实业有限公司(简称“上海宏桐”)取得一项医疗器械注册证和一项医疗器械变更注册文件，产品名称分别为：心脏脉冲电场消融仪、三维心脏电生理标测系统。上述医疗器械注册证的取得，有利于丰富公司的产品种类，扩充公司在电生理领域产品布局，不断满足多元化的临床需求，进一步增强公司的核心竞争能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","BK1583","688617","BK1222","BK1574","BK1100","09997","159883","09996"],"gpt_icon":0},{"id":"2492614379","title":"惠泰医疗大跌 近期券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2492614379","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492614379?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:42","pubTimestamp":1734313377,"startTime":"0","endTime":"0","summary":"12月16日，惠泰医疗股价大幅下跌，截至09点42分，惠泰医疗下跌5.06%，报346.50元/股，成交9410万元，换手率0.27%，振幅4.38%。资金动向截止发稿，惠泰医疗获得主力净流出776万元，其中超大单流入32万元，大单流出808万元。主营业务及业绩惠泰医疗公司主营业务为电生理和血管介入医疗器械的研发、生产和销售。最新财报显示，今年三季报，惠泰医疗实现营业收入15.25亿元，同比增长25.63%，净利润为5.28亿元，同比增长30.97%，基本每股收益为5.44元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216094303a1f1aed8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216094303a1f1aed8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2491523378","title":"惠泰医疗(688617.SH)：上海瑞康通拟引入新增股东上海康限 优化股东结构","url":"https://stock-news.laohu8.com/highlight/detail?id=2491523378","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491523378?lang=zh_cn&edition=full","pubTime":"2024-12-13 21:52","pubTimestamp":1734097928,"startTime":"0","endTime":"0","summary":"智通财经APP讯，惠泰医疗(688617.SH)公告，公司全资子公司湖南埃普特医疗器械有限公司(简称“埃普特”)系瑞康通(上海)科技发展有限公司(简称“上海瑞康通”)的股东。上海瑞康通股东上海惠技企业管理中心(有限合伙)(简称“上海惠技”)拟将其持有的1.7880%上海瑞康通股权转让给上海康限企业管理中心(有限合伙)(简称“上海康限”)，转让金额为340万元。上海瑞康通本次引入新增股东上海康限主要系随着其逐步发展，拟通过引入外部投资者、优化股东结构，为上海瑞康通的持续发展奠定良好的公司治理结构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2491301529","title":"惠泰医疗：向上海宏桐增资7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491301529","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491301529?lang=zh_cn&edition=full","pubTime":"2024-12-13 21:36","pubTimestamp":1734096986,"startTime":"0","endTime":"0","summary":"（原标题：惠泰医疗(688617.SH)：向上海宏桐增资7亿元）格隆汇12月13日丨惠泰医疗(688617.SH)公布，公司于2024年12月12日召开了第二届董事会第二十次会议和第二届监事会第十七次会议，审议通过了《关于使用募集资金及自有资金向全资子公司增资的的议案》，同意公司向全资子公司上海宏桐实业有限公司(以下简称“上海宏桐”)增资70,000.00万元，其中使用募集资金向上海宏桐提供的有息借款43,776.29万元(含截止2024年10月31日，募集资金的利息收益)转为对其增资，使用自有资金增资26,223.71万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213214307a1ec1a70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213214307a1ec1a70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2491320407","title":"惠泰医疗最新公告：使用募集资金及自有资金向全资子公司增资7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491320407","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491320407?lang=zh_cn&edition=full","pubTime":"2024-12-13 21:36","pubTimestamp":1734096979,"startTime":"0","endTime":"0","summary":"惠泰医疗公告，公司于2024年12月12日召开第二届董事会第二十次会议和第二届监事会第十七次会议，审议通过了《关于使用募集资金及自有资金向全资子公司增资的议案》，同意公司向全资子公司上海宏桐实业有限公司增资70,000.00万元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300045227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2491301577","title":"惠泰医疗：“血管介入类医疗器械产业化升级项目”予以结项","url":"https://stock-news.laohu8.com/highlight/detail?id=2491301577","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491301577?lang=zh_cn&edition=full","pubTime":"2024-12-13 21:35","pubTimestamp":1734096920,"startTime":"0","endTime":"0","summary":"（原标题：惠泰医疗(688617.SH)：“血管介入类医疗器械产业化升级项目”予以结项）格隆汇12月13日丨惠泰医疗(688617.SH)公布，截至2024年9月30日，“血管介入类医疗器械产业化升级项目”已完成全部建设且达到预定可使用状态。上述募投项目节余募集资金金额包含募投项目尚待支付的合同尾款、质保金等款项且款项支付时间周期较长，为提高资金使用效率、避免资金长期闲置，公司拟将上述募投项目结项后的节余募集资金1,455.60万元（实际金额以资金转出当日专户余额为准）永久补充流动资金，用于公司日常生产经营及业务发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213214251a1ec1a48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213214251a1ec1a48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688617","BK0251","159883"],"gpt_icon":0},{"id":"2491582304","title":"惠泰医疗：埃普特放弃对参股公司上海瑞康通股权转让的优先购买权","url":"https://stock-news.laohu8.com/highlight/detail?id=2491582304","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491582304?lang=zh_cn&edition=full","pubTime":"2024-12-13 21:34","pubTimestamp":1734096844,"startTime":"0","endTime":"0","summary":"格隆汇12月13日丨惠泰医疗公布，公司全资子公司湖南埃普特医疗器械有限公司系瑞康通(上海)科技发展有限公司的股东，持有湖南瑞康通30.8839%的股权。因上海惠技、上海康限系公司关联方，埃普特拟放弃对本次转让中的优先购买权构成公司与关联方之间的关联交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213214248ab757429&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213214248ab757429&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2491342547","title":"惠泰医疗12月13日现1笔大宗交易 成交金额507.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491342547","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491342547?lang=zh_cn&edition=full","pubTime":"2024-12-13 17:40","pubTimestamp":1734082800,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　12月13日，惠泰医疗收跌0.28%，收盘价为364.96元，发生1笔大宗交易，合计成交量1.39万股，成交金额507.29万元。　　第1笔成交价格为364.96元，成交1.39万股，成交金额507.29万元，溢价率为0.00%，买方营业部为中信证券股份有限公司上海分公司，卖方营业部为机构专用。　　进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为2790.34万元。该股近5个交易日累计下跌4.96%，主力资金合计净流出1.13亿元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-12-13/doc-inczikpp2640319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688617","BK0251"],"gpt_icon":0},{"id":"2491341987","title":"12月13日惠泰医疗现1笔大宗交易 机构净卖出507.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491341987","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491341987?lang=zh_cn&edition=full","pubTime":"2024-12-13 17:21","pubTimestamp":1734081671,"startTime":"0","endTime":"0","summary":"证券之星消息，12月13日惠泰医疗发生大宗交易，交易数据如下：大宗交易成交价格364.96元，成交1.39万股，成交金额507.29万元，买方营业部为中信证券股份有限公司上海分公司，卖方营业部为机构专用。近三个月该股共发生2笔大宗交易，合计成交839.0手，折价成交1笔。该股在过去半年内已有共计42.37万股限售解禁股上市，占公司总股本的0.44%。截至2024年12月13日收盘，惠泰医疗报收于364.96元，下跌0.28%，换手率1.79%，成交量1.75万手，成交额6.28亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300030242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688617","BK0251"],"gpt_icon":0},{"id":"2491334154","title":"惠泰医疗12月12日收涨1.12% 主力资金逆市抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2491334154","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491334154?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:19","pubTimestamp":1733987980,"startTime":"0","endTime":"0","summary":"12月12日, 惠泰医疗股价涨1.12%，报收365.99元，成交金额3.54亿元，换手率1.01%，振幅3.32%，量比1.48。惠泰医疗今日主力资金净流出4587万元，上一交易日主力净流入979万元。该股近5个交易日下跌3.06%，主力资金累计净流出4826万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出6316万元，其中净流出天数为9日。净流出前三个股分别为新产业、惠泰医疗、鱼跃医疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212153418ab71c344&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212153418ab71c344&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2490715670","title":"惠泰医疗（688617）12月10日主力资金净卖出439.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490715670","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490715670?lang=zh_cn&edition=full","pubTime":"2024-12-11 08:24","pubTimestamp":1733876661,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月10日收盘，惠泰医疗报收于366.33元，下跌1.66%，换手率0.85%，成交量8247.0手，成交额3.06亿元。近5日资金流向一览见下表：惠泰医疗融资融券信息显示，融资方面，当日融资买入3146.08万元，融资偿还2057.83万元，融资净买入1088.25万元，连续3日净买入累计1571.45万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121100007409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688617"],"gpt_icon":0},{"id":"2486387128","title":"1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2486387128","media":"汇添富基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486387128?lang=zh_cn&edition=full","pubTime":"2024-11-28 08:11","pubTimestamp":1732752682,"startTime":"0","endTime":"0","summary":"消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。国金证券表示，由于多方面因素，医药板块景气度在2021年后经历了长时间的下行。2024年11月7日，国家医保局召开了座谈会，强调了全国统一医保平台和大数据赋能商保发展的重要性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688139","688356","688575","688266","688670","600535","688617","603301","BK0185","600252","688105","600771","605199","600422","688247","603259","688506","600511","603658","688176","600721","600161","688276","600572","600200","603439","603707","688029","603309","688137","688046","600436","688488","603127","688091","688298","600055","688198","603882","688050","603538","688271","603896","600998","688212","600488","600739","600529","BK0028","688520","BK0188","688177","600211","688336","600085","688581","600129","688062","BK0070","600062","688626","688443","BK0012","605177","600867","688235","600079","603939","688180","688192","688166","688301","600080","688278","600763","688193","688656","688161","603233","600566","603567","600521","603392","688321","688687","688117","603456","688202","688315","600196","603590","688382","688067","159938","688085","688373","603108","688767","600285","600380","601607","688114","688351","688578","688389","BK0096","688566","688189","600976","688428","600056","688690","BK0239","600276","688222","603367","688076","600329","600420","600332","600851","688331","603087","688073","600351","688658","603858","688163","688221"],"gpt_icon":0},{"id":"2486946758","title":"惠泰医疗：房颤相关耗材预计在今年年底或明年年初获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2486946758","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486946758?lang=zh_cn&edition=full","pubTime":"2024-11-27 13:49","pubTimestamp":1732686552,"startTime":"0","endTime":"0","summary":"11月27日，惠泰医疗举办2024年第三季度业绩说明会。会上管理层介绍，房颤相关耗材预计在今年年底或明年年初获批。房颤的相关耗材在获批后需要进行国家医保C码申请、省级准入等工作。一般在获证6-9个月后开始入院销售。对于迈瑞与惠泰的资源整合进度，管理层介绍，迈瑞与惠泰的资源整合与协同，正在按计划有序进行中，从目前看，基于双方对整体业务方向和企业发展目标的高度一致，整体进度符合预期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127135008a258ec8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127135008a258ec8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688617","BK0251"],"gpt_icon":0},{"id":"2485814238","title":"惠泰医疗：产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2485814238","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485814238?lang=zh_cn&edition=full","pubTime":"2024-11-22 15:50","pubTimestamp":1732261826,"startTime":"0","endTime":"0","summary":"每经AI快讯，惠泰医疗 11月22日晚间发布公告称，2024年11月21日，深圳惠泰医疗器械股份有限公司全资子公司湖南埃普特医疗器械有限公司获得一项医疗器械注册证。2023年1至12月份，惠泰医疗的营业收入构成为：医疗器械占比99.49%。惠泰医疗的董事长是葛昊，男，40岁，学历背景为硕士；总经理是成正辉，男，60岁，学历背景为硕士。截至发稿，惠泰医疗市值为340亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122155129a24d5695&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122155129a24d5695&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688617","BK0251"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-01-07","address":"广东省深圳市南山区西丽街道松坪山社区松坪山朗山路11号同方信息港B栋601","stockEarnings":[{"period":"1week","weight":-0.0513},{"period":"1month","weight":-0.0707},{"period":"3month","weight":0.0324},{"period":"6month","weight":0.1483},{"period":"1year","weight":0.3538},{"period":"ytd","weight":0.2978}],"companyName":"深圳惠泰医疗器械股份有限公司","boardCode":"AI0035","perCapita":"24378股","boardName":"专用设备制造业","registeredCapital":"9739万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":"　　深圳惠泰医疗器械股份有限公司的主营业务为心血管介入医疗器械的研发、生产和销售；主要产品是电生理、冠脉通路、外周血管介入、非血管介入医疗器械。公司的电生理电极导管和射频消融电极导管均为国内首个获批上市的国产产品，先发优势助力公司成为国内电生理市场中国生产厂商的龙头企业。","serverTime":1734780329934,"listedPrice":74.46,"stockholders":"3995人(较上一季度增加17.64%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"惠泰医疗(688617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供惠泰医疗(688617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"惠泰医疗,688617,惠泰医疗股票,惠泰医疗股票老虎,惠泰医疗股票老虎国际,惠泰医疗行情,惠泰医疗股票行情,惠泰医疗股价,惠泰医疗股市,惠泰医疗股票价格,惠泰医疗股票交易,惠泰医疗股票购买,惠泰医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"惠泰医疗(688617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供惠泰医疗(688617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}